Home/Pipeline/Multiple undisclosed candidates

Multiple undisclosed candidates

Oncology and other serious unmet needs

Phase 1/Phase 2Active

Key Facts

Indication
Oncology and other serious unmet needs
Phase
Phase 1/Phase 2
Status
Active
Company

About Chugai Pharma

Chugai Pharma USA is the U.S. strategic arm of Chugai Pharmaceutical Co., Ltd., a member of the Roche Group. Its core function is to support the clinical development of Chugai's innovative small molecule and biotechnology products for the global market, with a focus on oncology and other areas of high unmet medical need. The subsidiary leverages Chugai's proven R&D capabilities, exemplified by blockbuster drugs like Actemra, Alecensa, and Hemlibra, to advance its independent pipeline through early proof-of-concept before potential partnership with Roche for late-stage development. CPUSA operates as a clinical development and strategic planning hub, critical for Chugai's ambitions in the key U.S. pharmaceutical market.

View full company profile